Related Experiment Video
Updated: Sep 11, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer
Qiaochang Cao1, Siqi Ding1, Xueer Zheng1
1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang 310006, PR China.
Background:
Ferroptosis is pivotal in colon cancer progression and immunity. While the natural flavonoid luteolin has anticancer properties, its ferroptosis targets and immunomodulatory effects in colon cancer are unclear.
Purpose:
This study aims to validate luteolin's anticancer efficacy in colon cancer and elucidate its mechanism involving ferroptosis induction and antitumor immune activation.
Methods:
Integrated WGCNA, machine learning, and functional enrichment techniques to analyze luteolin's potential targets. Comprehensive assays including CCK-8, colony formation, flow cytometry, western blotting, and reactive oxygen species (ROS)/malondialdehyde (MDA)/glutathione (GSH) /FerroOrange profiling, combined with MC38 syngeneic models, were used to investigate luteolin's antiproliferative effects, glutathione peroxidase 4 (GPX4) - dependent ferroptosis induction, and modulation of tumor-infiltrating immune cells. Molecular docking, Cellular Thermal Shift Assay (CETSA), Drug Affinity Responsive Target Stability (DARTS), and surface plasmon resonance (SPR) validated GPX4-luteolin interactions. Anti-CD8 antibody and clodronate liposomes (CLD) immune depletion studies demonstrate that CD8⁺ T cells and macrophages play pivotal roles in activating antitumor immunity.
Results:
Bioinformatics indicated luteolin modulates oxidative stress signaling. Luteolin dose-dependently inhibited colon cancer cell proliferation, reversed by ferroptosis inhibitor Ferrostatin-1. Luteolin triggered ROS/Fe2+ accumulation, lipid peroxidation, MDA elevation, GSH depletion, and GPX4 downregulation. GPX4 overexpression conferred ferroptosis resistance, reversed by luteolin. Besides, luteolin directly bound GPX4, enhancing its thermal stability and suppressing pronase E-mediated degradation. In vivo, luteolin exhibited antitumor efficacy through GPX4 downregulation and ferroptosis induction, synergistically promoting intratumoral M1 macrophage polarization and CD8+ T lymphocyte activation.
Conclusion:
Luteolin induces ferroptosis by directly targeting GPX4, and promotes antitumor immune responses. These findings reveal a novel mechanism underlying luteolin-induced ferroptosis and provide theoretical support for its immunotherapeutic application in colon cancer.
